On Friday, Following stocks ended their trade in “Red -Zone“: Sunesis Pharmaceuticals, (NASDAQ:SNSS), Alder Biopharmaceuticals (NASDAQ:ALDR), Tenet Healthcare (NYSE:THC), Neurocrine Biosciences, (NASDAQ:NBIX)
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), stated pecuniary results for the fourth quarter and year ended December 31, 2014. Loss from operations for the three months and year ended December 31, 2014 was $11.2 million and $45.0 million, correspondingly. As of December 31, 2014, cash, cash equivalents and profitable securities totaled $43.0 million
The fourth quarter of 2014 was a central period for Sunesis and vosaroxin, with unbinding of our Phase 3 VALOR trial in October and the agreement in December of the full results at the late breaking abstract forum of ASH.”
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) decreased -1.52%, and closed at $2.60. The company holds the market capitalization of $176.12M. For the last twelve months, the stock was able to keep return on equity at -291.50%, while return on assets at –77.50%, in response to its return on investment at -195.20%. Its 20-day moving average gained 13.09%, above 50-day moving average of 9.73%, below 200-day moving average of -36.60% from the latest market price of $2.60. The mean recommendation of analysts for this stock is 2.50. (Where 1=Buy, 5=Sale).
Sunesis Pharmaceuticals, Inc. (SNSS) a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) a clinical-stage biopharmaceutical corporation developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, declared that it reported its fourth quarter and full year 2014 monetary and operating results after the close of U.S. financial markets on Wednesday, March 4, 2015.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) declined -1.49%, and closed at $29.01. The company has the market capitalization of $1.12 billion. On the other hand the stock’s volatility for the week is 5.64%, and for the month is 6.65%. The stock’s price to book ratio is $13.75, however price to sale ratio is $20.10. Analyst’s mean recommendation regarding this stock is 1.30. (Where 1=Buy, 5=Sale).
Alder Biopharmaceuticals Inc (ALDR) a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia.
Tenet Healthcare Corp (NYSE:THC) has selected Tammy Romo, senior vice leader of finance and chief financial officer of Southwest Airlines Co., as a new independent director. Romo becomes the board’s tenth member. She will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
Romo, 52, has served as senior vice president of investment and chief financial officer of Southwest Airlines since September 2012. She is responsible for strategic preparation and overall finance behavior at the company, including financial reporting, secretarial, investor relations, treasury, tax, and financial scheduling and analysis
Tenet Healthcare Corp (NYSE:THC) decreased -1.49%, and closed at $49.62. The stock has price to sale ratio of 0.29, however, price to book ratio is 7.50. With recent decline, the year-to-date (YTD) performance reflected a -4.34% decline. During the past month the stock gained 10.64%, bringing three-month performance to -4.3% and six-month performance to -21.57%. The mean recommendation of analysts for this stock is 2.20 (where 1=Buy, 5=Sale).
Tenet Healthcare Corp (THC) a healthcare services company, primarily operates acute care hospitals and related healthcare facilities in the United States. It operates through two segments, Hospital Operations and Other, and Conifer. The company’s general hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) declared that Kevin Gorman, head and Chief supervisory detective of Neurocrine Biosciences, will be presenting at the Barclays Global Healthcare meeting in Miami.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares picked down -1.47%, and closed at $43.60, hitting new 52-week low of $45.36. The stock volatility for the week is 3.25%, while for the month remained 3.97%. The company holds consensus target price of $46.86.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.81 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -17.40% and Annual EPS growth for the past 5 years is considered as 9.00%.
The mean recommendation of analysts for this stock is 1.80. (Where 1=Buy, 5=Sale).
Neurocrine Biosciences, Inc. (NBIX) discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage include elagolix.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
